Attrition rates are high during the early stages of biopharmaceutical development which impacts the cost and time to first in human studies. Identification of the preferred expression host for manufacturing, along with lead candidate screening and material supply can help to optimize for clinical success. As protein therapeutics become more complex, the use of early stage in vitro expression to assess and identify product and manufacturing risks enable the development of process strategies to mitigate these threats as early as possible and maximize the outcome of development efforts. Early genetic assessment of expression cell lines can support cell line characterisation and can help to confirm identify stability concerns.

This webinar will describe strategies to mitigate risks, reduce attrition and help improve the quality and safety of your drug candidate.
You may also be interested in:
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content
Latest briefing from the Knowledge Center